表紙
市場調查報告書

女性特有的各種疾病的治療藥:全球市場的預測

Pharmaceuticals for Women's Health: Global Markets to 2023

出版商 BCC Research 商品編碼 660275
出版日期 內容資訊 英文 141 Pages
訂單完成後即時交付
價格
女性特有的各種疾病的治療藥:全球市場的預測 Pharmaceuticals for Women's Health: Global Markets to 2023
出版日期: 2018年07月03日內容資訊: 英文 141 Pages
簡介

全球女性特有的各種疾病的治療藥的市場在預測期間內,預計以4.2%的年複合成長率發展,從2018年的305億美元,成長至2023年的373億美元的規模。

本報告提供全球女性特有的各種疾病的治療藥的市場調查,市場定義、背景,市場成長的各種影響因素及市場機會分析,開發平台趨勢,各地區的相關法律藥價設定、償付趨勢,各疾病、地區/主要國家趨勢與市場規模的變化與預測,競爭環境,主要企業簡介等彙整。

第1章 簡介

第2章 摘要、亮點

第3章 各種技術、市場概要

  • 疾病概要、定義
  • 市場成長的促進因素與市場機會
  • 市場成長的阻礙因素

第4章 開發平台的評估、分析

  • 開發平台藥物的清單
    • 概要:骨質疏鬆症治療藥的開發平台
  • 開發平台後期的藥物
    • Elagolix (AbbVie Inc.)
    • Vilaprisan (Bayer AG)
    • Evenity (Amgen Inc.)
    • Relugolix (Myovant Sciences)
    • Proellex (Repros Therapeutics)
    • Esmya (Allergan Inc.)
    • TX-004HR (TherapeuticsMD, Inc.)
    • TX-001HR (TherapeuticsMD, Inc.)

第5章 法律規章結構

  • 概要:法律規章
    • 美國
    • 加拿大
    • 歐洲
    • 日本
  • 概要:藥價設定、償付
    • 美國
    • 加拿大
    • 歐洲
    • 日本

第6章 市場分析、預測:各疾病

  • 簡介
  • 閉經伴隨的疾病
    • 概要
    • 症狀
    • 風險要素
    • 流行病學、經濟負擔
    • 診斷
    • 治療
    • 市場規模、預測
  • 停經後骨質疏鬆症
    • 概要
    • 流行病學、經濟負擔
    • 診斷
    • 治療
    • 市場規模、預測
  • 子宮內膜異位症
    • 概要
    • 流行病學、經濟負擔
    • 診斷
    • 治療
    • 市場規模、預測
  • 多囊性卵巢症候群 (PCOS)
    • 概要
    • PCOS的風險的降低
    • 流行病學、經濟負擔
    • 診斷
    • 治療
    • 市場規模、預測
  • 妊娠中的疾病、管理
    • 概要
    • 市場規模、預測
    • 其他
    • 概要
    • 市場規模、預測

第7章 市場分析、預測:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 其他
  • 南美
  • 中東、非洲

第8章 競爭環境、主要的部署

  • 主要企業、策略
  • 專利分析
    • 主要專利的清單
  • 主要的部署
    • M&A
    • 創新的產品的開發、新產品的投入
    • 協定、聯盟、合作
  • 主要產品

第9章 企業簡介

  • ABBVIE INC.
  • ALLERGAN PLC.
  • AMGEN INC.
  • BAYER AG
  • 第一三共
  • ELI LILLY AND COMPANY
  • JOHNSON & JOHNSON INC.
  • MERCK & CO. INC.
  • MERCK KGAA
  • NOVO NORDISK
  • PFIZER INC.

第10章 附錄

目錄
Product Code: PHM203A

Highlights:

The global market for women’s health therapeutics reached nearly $30.5 billion in 2018 and should reach nearly $37.3 billion by 2023, at a compound annual growth rate (CAGR) of 4.2% for the period of 2018-2023.

Postmenopausal osteoporosis market for women’s health therapeutics reached $9.1 billion in 2018 and should reach $11.6 billion by 2023 at a CAGR of 4.9% through 2023.

Menopause market for women’s health therapeutics reached $5.4 billion in 2018 and should reach $6.7 billion by 2023 at a CAGR of 4.5% through 2023.

Report Scope:

While women's health encompasses several health issues, this report will focus on menopause-related disorders, postmenopausal osteoporosis, endometriosis, polycystic ovarian syndrome and pregnancy disorders. This report does not focus on drugs for infertility, diagnostic and drug technologies for breast cancer or therapies and diagnostics for ovarian cancer. However, we have individuals reports which discusses the scope of these health concerns in detail. The report codes for these reports are listed below:

  • PHM194A Drugs for Infertility: Global Markets.
  • HLC143B Therapies and Diagnostics for Ovarian Cancer: Global Markets.
  • HLC209A U.S. Fertility Clinics Market.
  • HLC106B Breast Cancer Diagnostic and Drug Technologies: Global Markets.

Report Includes:

  • 26 data tables and 34 additional tables
  • Detailed overview of the global markets for pharmaceuticals for women's health
  • Country specific data and analysis for United States, Mexico, Germany, U.K., France, China, India, Japan, Middle East and Africa
  • A look at the regulatory environment which has been a driving force in the drug development industry
  • Information on competitor initiatives, and information with regard to demand for specialty chemicals used to develop new products and for new applications
  • A relevant patent analysis within the sector
  • Comprehensive company profiles of major Players in the Market including AbbVie Inc., Allergan PLC, Amgen Inc., Bayer Ag., Eli Lilly and Company, Johnson & Johnson Inc., Novo Nordisk and Pfizer Inc.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Technologies and Global Markets Overview

  • Disease Overview and Definitions
  • Market Driving Factors and Opportunities
    • Aging Female Population
    • Government Involvement and Increased Funding
    • Increasing Awareness Regarding Women's Disorders and Treatments
  • Market Restraints
    • Poor Diagnosis
    • Availability of Alternate Treatment Options and Lifestyle Changes
    • Unavailability of Novel Treatments
    • High Cost of Treatment

Chapter 4: Pipeline Assessment and Analysis

  • List of Drugs in Pipeline
    • Overview of Osteoporosis Drug Development Pipeline
  • Late-stage Pipeline Drugs
    • Elagolix (AbbVie Inc.)
    • Vilaprisan (Bayer AG)
    • Evenity (Amgen Inc.)
    • Relugolix (Myovant Sciences)
    • Proellex (Repros Therapeutics)
    • Esmya (Allergan Inc.)
    • TX-004HR (TherapeuticsMD, Inc.)
    • TX-001HR (TherapeuticsMD, Inc.)

Chapter 5: Regulatory Structure

  • Overview of Regulations
    • United States
    • Canada
    • Europe
    • Japan
  • Overview of Pricing and Reimbursement
    • United States
    • Canada
    • Europe
    • Japan

Chapter 6: Market Breakdown by Women's Health Disorders

  • Introduction
  • Menopause-Related Diseases
    • Overview
    • Symptoms
    • Risk Factors
    • Epidemiology and Economic Burden
    • Diagnosis
    • Treatments
    • Market Size and Forecasts
  • Postmenopausal Osteoporosis
    • Overview
    • Epidemiology and Economic Burden
    • Diagnosis
    • Treatments
    • Market Size and Forecasts
  • Endometriosis
    • Overview
    • Epidemiology and Economic Burden
    • Diagnosis
    • Treatments
    • Market Size and Forecasts
  • Polycystic Ovary Syndrome (PCOS)
    • Overview
    • Reducing the Risk of PCOS
    • Epidemiology and Economic Burden
    • Diagnosis
    • Treatments
    • Market Size and Forecasts
  • Pregnancy Disorders and Management
    • Overview
    • Market Size and Forecasts
  • Others
    • Overview
    • Market Size and Forecasts

Chapter 7: Market Breakdown by Region

  • Introduction
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia-Pacific
  • South America
  • Middle East and Africa

Chapter 8: Competitive Landscape and Key Developments

  • Market Players and Strategy
  • Patent Analysis
    • List of Key Patents
  • Key Developments
    • Mergers and Acquisitions
    • Development of Innovative Products/Novel Product Launch
    • Agreements, Collaborations & Partnerships
  • Key Products

Chapter 9: Company Profiles

  • ABBVIE INC.
    • Company Overview
    • Product Information
    • Development and Strategies
    • Financials
  • ALLERGAN PLC.
    • Company Overview
    • Product Information
    • Development and Strategies
    • Financials
  • AMGEN INC.
    • Company Overview
    • Product Information
    • Development and Strategies
    • Financials
  • BAYER AG
    • Company Overview
    • Product Information
    • Development and Strategies
    • Financials
  • DAIICHI SANKYO COMPANY. LTD.
    • Company Overview
    • Product Information
    • Development and Strategies
    • Financials
  • ELI LILLY AND COMPANY
    • Company Overview
    • Product Information
    • Development and Strategies
    • Financials
  • JOHNSON & JOHNSON INC.
    • Company Overview
    • Product Information
    • Financials
  • MERCK & CO. INC.
    • Company Overview
    • Product Information
    • Development and Strategies
    • Financials
  • MERCK KGAA
    • Company Overview
    • Product Information
  • NOVO NORDISK
    • Company Overview
    • Product Information
    • Financials
  • PFIZER INC.
    • Company Overview
    • Product Information
    • Development and Strategies
    • Financials

Chapter 10: Appendix

  • Abbreviations Used in the Report

List of Tables

  • Summary Table: Global Market for Women's Health Therapeutics, by Disease Area, Through 2023
    • Table 1: Life Expectancy at Birth, Both Sexes Combined, by Region
    • Table 2: Pipeline Molecules, Endometriosis
    • Table 3: Pipeline Molecules, Uterine Fibroids
    • Table 4: Pipeline Molecules, All Other Indications
    • Table 5: Pipeline Molecules, Osteoporosis
    • Table 6: Elagolix Snapshot
    • Table 7: Vilaprisan Snapshot
    • Table 8: Evenity Snapshot
    • Table 9: Relugolix Snapshot
    • Table 10: Proellex Snapshot
    • Table 11: Esmya Snapshot
    • Table 12: TX-004HR Snapshot
    • Table 13: TX-001HR Snapshot
    • Table 14: Global Market for Women's Health Therapeutics, by Disease Area, Through 2023
    • Table 15: FDA Approved Estrogen-only Medicines
    • Table 16: FDA Approved Progestin-only Medicines
    • Table 17: FDA Approved Combination, Estrogen and Progestin Medicines
    • Table 18: FDA Approved Combination Estrogen and Hormone Medicines
    • Table 19: Vagifem (10mcg), Patent Expiration
    • Table 20: Global Menopause Market, by Region, Through 2023
    • Table 21: Prolia/XGEVA (Denosumab) Patent Expiration
    • Table 22: Global Postmenopausal Osteoporosis Market, by Region, Through 2023
    • Table 23: Global Endometriosis Market, by Region, Through 2023
    • Table 24: Global Polycystic Ovary Syndrome Market, by Region, Through 2023
    • Table 25: Global Pregnancy Disorders and Management Market, by Region, Through 2023
    • Table 26: Global Women's Health Therapeutics Others Market, by Region, Through 2023
    • Table 27: Global Women's Health Therapeutics, by Region, Through 2023
    • Table 28: North American Market for Women's Health Therapeutics, by Disease Area Through 2023
    • Table 29: European Market for Women's Health Therapeutics, by Disease Area, Through 2023
    • Table 30: Asia Pacific Market for Women's Health Therapeutics, by Disease Area, Through 2023
    • Table 31: South America Market for Women's Health Therapeutics, by Disease Area, Through 2023
    • Table 32: Middle East and Africa Market for Women's Health Therapeutics, by Disease Area, Through 2023
    • Table 33: Company Share Analysis, by Indication, 2017
    • Table 34: Tier III Companies
    • Table 35: Patent Review
    • Table 36: Marketed Products, Postmenopausal Osteoporosis
    • Table 37: AbbVie Inc., Marketed Products
    • Table 38: AbbVie Inc., Net Revenue, 2015-2017
    • Table 39: Allergan Plc., Marketed Products
    • Table 40: Allergan Plc., Net Revenue, 2015-2017
    • Table 41: Amgen Inc., Marketed Products, 2016
    • Table 42: Amgen Inc.: Net Revenue, 2015-2017
    • Table 43: Bayer AG, Marketed Products
    • Table 44: Bayer AG, Net Revenue, 2015-2017
    • Table 45: Daiichi Sankyo Company. Ltd., Marketed Products
    • Table 46: Daiichi Sankyo Company Ltd. Net Revenue 2015-2017
    • Table 47: Eli Lilly and Company, Marketed Products
    • Table 48: Eli Lilly and Company Net Revenue, 2015-2017
    • Table 49: Johnson & Johnson Inc., Marketed Products, 2016
    • Table 50: Johnson & Johnson Inc. Net Revenue, 2014-2016
    • Table 51: Merck & Co. Inc. Marketed Products
    • Table 52: Merck & Co. Inc. Net Revenue, 2014-2016
    • Table 53: Merck KGaA Marketed Products
    • Table 54: Novo Nordisk, Marketed Products
    • Table 55: Novo Nordisk, Net Revenue, 2015-2017
    • Table 56: Pfizer Inc. Marketed Products by Indication, 2016
    • Table 57: Pfizer Inc. Net Revenue, 2014-2016
    • Table 58: Glossary of Terms Used in Women's Health Therapeutics
    • Table 59: Abbreviations Used in Women's Health Therapeutics

List of Figures

  • Summary Figure: Global Market for Women's Health Therapeutics, by Disease Area, 2017-2023
    • Figure 1: Older Population Distribution, by Age Group and Sex, 2017
    • Figure 2: Older Population Distribution, by Age Group and Sex, 2050
    • Figure 3: Funding for Research, Disease Condition/Category, 2014-2016
    • Figure 4: Funding for Research, Women's Health, 2014-2016
    • Figure 5: Insurance Coverage in the U.S., by Healthcare Providers, 2014
    • Figure 6: Global Women's Health Therapeutics Market, 2017-2023
    • Figure 7: Global Women's Health Therapeutics Market Share, by Disease Area, 2018
    • Figure 8: Global Women's Health Therapeutics Market Share, by Disease Area, 2023
    • Figure 9: Global Menopause Market, 2017-2023
    • Figure 10: Global Menopause Market, by Region, 2017-2023
    • Figure 11: Australia Rate of Hospitalization for Osteoporosis, People Aged 50 and Over, 2015-2016
    • Figure 12: Global Postmenopausal Osteoporosis Market, 2017-2023
    • Figure 13: Global Postmenopausal Osteoporosis Market, by Region, 2017-2023
    • Figure 14: Global Endometriosis Market, 2017-2023
    • Figure 15: Global Endometriosis Market, by Region, 2017-2023
    • Figure 16: Global Polycystic Ovary Syndrome Market, 2017-2023
    • Figure 17: Global Polycystic Ovary Syndrome Market, by Region, 2017-2023
    • Figure 18: Global Pregnancy Disorders and Management Market, 2017-2023
    • Figure 19: Global Pregnancy Disorders and Management Market, by Region, 2017-2023
    • Figure 20: Global Women's Health Therapeutics Market for Others, 2017-2023
    • Figure 21: Global Women's Health Therapeutics Others Market, 2017-2023
    • Figure 22: Global Women's Health Therapeutics Market, by Region, 2017-2023
    • Figure 23: North America Women's Health Therapeutics Market, 2017-2023
    • Figure 24: North America Women's Health Therapeutics Market Share, by Disease Area, 2018
    • Figure 25: North America Women's Health Therapeutics Market Share, by Disease Area, 2023
    • Figure 26: North America Market for Women's Health Therapeutics, by Country, 2017-2023
    • Figure 27: United States Women's Health Therapeutics Market, 2017- 2023
    • Figure 28: Canada Women's Health Therapeutics Market, 2017-2023 ($ Millions)
    • Figure 29: Mexico Women's Health Therapeutics Market, 2017-2023
    • Figure 30: Europe Women's Health Therapeutics Market, 2017-2023
    • Figure 31: Europe Women's Health Therapeutics Market Share, by Disease Area, 2018
    • Figure 32: Europe Women's Health Therapeutics Market Share, by Disease Area, 2023
    • Figure 33: Europe Market for Women's Health Therapeutics, by Country, 2017-2023
    • Figure 34: United Kingdom Women's Health Therapeutics Market, 2017-2023
    • Figure 35: Germany Women's Health Therapeutics Market, 2017-2023
    • Figure 36: France Women's Health Therapeutics Market, 2017-2023
    • Figure 37: Spain Women's Health Therapeutics Market, 2017-2023
    • Figure 38: Italy Women's Health Therapeutics Market, 2017-2023
    • Figure 39: Rest of Europe Women's Health Therapeutics Market, 2017-2023
    • Figure 40: Asia-Pacific Women's Health Therapeutics Market, 2017-2023
    • Figure 41: Asia-Pacific Women's Health Therapeutics Market Share, by Disease Area, 2018
    • Figure 42: Asia-Pacific Women's Health Therapeutics Market Share, by Disease Area, 2023
    • Figure 43: Asia Pacific Market for Women's Health Therapeutics, by Country, 2017-2023
    • Figure 44: China Women's Health Therapeutics Market, 2017-2023
    • Figure 45: Japan Women's Health Therapeutics Market, 2017-2023
    • Figure 46: India Women's Health Therapeutics Market, 2017-2023
    • Figure 47: South Korea Women's Health Therapeutics Market, 2017-2023
    • Figure 48: Asia-Pacific Women's Health Therapeutics Market, 2017-2023
    • Figure 49: South America Women's Health Therapeutics Market, 2017-2023
    • Figure 50: South America Women's Health Therapeutics Market Share, by Disease Area, 2018
    • Figure 51: South America Women's Health Therapeutics Market Share, by Disease Area, 2023
    • Figure 52: Middle East & Africa Women's Health Therapeutics Market, 2017-2023
    • Figure 53: Middle East & Africa Women's Health Therapeutics Market Share, by Disease Area, 2018
    • Figure 54: Middle East & Africa Women's Health Therapeutics Market Share, by Disease Area, 2023
    • Figure 55: Global Women's Health Therapeutics Market Share Analysis, 2017
    • Figure 56: AbbVie Inc., Revenue Share, by Region, 2016
    • Figure 57: Allergan PLC., Revenue Share, by Business Segment, 2016
    • Figure 58: Amgen Inc. R&D Expenditure, 2014-2016
    • Figure 59: Amgen Inc.: Revenue Share, by Region, 2017
    • Figure 60: Bayer AG, Revenue Share, by Region, 2017
    • Figure 61: Bayer AG, Revenue Share, by Business Segment, 2017
    • Figure 62: Daiichi Sankyo Company. Ltd., R&D Expenditure, 2014-2016
    • Figure 63: Daiichi Sankyo Company Revenue Share by Business Segment, 2016
    • Figure 64: Eli Lilly and Company Revenue Share by Business Segment, 2016
    • Figure 65: Eli Lilly and Company Revenue Share by Region, 2016
    • Figure 66: Johnson and Johnson Inc. Revenue Share, by Business Segment, 2016
    • Figure 67: Johnson and Johnson Inc. Revenue Share, by Region, 2016
    • Figure 68: Merck & Co. Inc. Revenue Share by Business Segment, 2016
    • Figure 69: Merck & Co. Inc. Revenue Share by Region, 2016
    • Figure 70: Novo Nordisk, Revenue Share, by Region, 2016
    • Figure 71: Novo Nordisk, Revenue Share, by Business Segment, 2016
    • Figure 72: Pfizer Inc. Revenue Share, by Region, 2016
    • Figure 73: Pfizer Inc. Revenue Share, by Business Segment, 2016